Brief: Pharnext Expects PREMIER Trial Topline Results In Q3 2023
21/06/2021 07:41
June 21 (Reuters) - PHARNEXT SA PHARN.PA :
* PREMIER TRIAL: ADDITIONAL SITES ARE PLANNED TO BE
ACTIVATED IN
US AND CANADA DURING SUMMER 2021 - SHAREHOLDER LETTER
* PREMIER TRIAL: WE ARE STILL ON TRACK TO ANNOUNCE
ACTIVATION OF
FIRST EU AND ISRAELI SITES IN Q3 2021 - SHAREHOLDER LETTER
* PREMIER TRIAL: WE ARE CONFIDENT THAT WE WILL COMPLETE
ENROLLMENT
IN PREMIER TRIAL IN Q2 2022 WHICH WILL ALLOW OUR COMPANY TO
DISCLOSE TOPLINE RESULTS OF PIVOTAL PHASE III STUDY IN Q3 2023 -
SHAREHOLDER LETTER
Source text for Eikon: ID:nEQ506ydfa
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development